Substance Use Stigma, Primary Care, and the New York State Prescription Drug Monitoring Program

被引:32
作者
Allen, Bennett [1 ]
Harocopos, Alex [1 ]
Chernick, Rachel [1 ]
机构
[1] Bur Alcohol & Drug Use Prevent Care & Treatment, New York City Dept Hlth & Mental Hyg, 42-09 28th St,19th Floor, Queens, NY 11101 USA
关键词
Opioid; prescription drug monitoring program; primary care; stigma; substance use; ELECTRONIC MEDICAL-RECORD; OPIOID PHARMACOVIGILANCE; PHYSICIANS PERSPECTIVES; USE DISORDERS; CLINICIAN USE; BUPRENORPHINE; BARRIERS; OVERDOSE; IMPACT; IMPLEMENTATION;
D O I
10.1080/08964289.2018.1555129
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Prescription drug monitoring programs (PDMPs) are databases that track controlled substances at the provider, patient, and pharmacy levels. While these databases are widely available at the state level throughout the United States, several jurisdictions in recent years have mandated the use of these systems by health care providers. This study explores the implementation of mandatory PDMP technology in primary care practice and the effects on treatment of people with possible substance use disorders. Findings are based on 53 in-depth interviews with primary care providers in New York City, collected shortly following the passage of legislation mandating use of a PDMP by health care providers in New York State. Findings suggest that use of the PDMP highlighted tensions between provider stigma toward substance use disorders and the clinical care of people who use drugs, challenging their stereotypes and biases. The parallel clinical and law enforcement purposes of PDMP technology placed providers in dual roles as clinicians and enforcers and encouraged the punitive treatment of patients. Finally, PDMP technology standardized the clinical assessment process toward a "diagnosis first" approach, consistent with prior scholarship on the implementation of emerging medical technologies.
引用
收藏
页码:52 / 62
页数:11
相关论文
共 59 条
[1]   Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health [J].
Ali, Mir M. ;
Dowd, William N. ;
Classen, Timothy ;
Mutter, Ryan ;
Novak, Scott P. .
ADDICTIVE BEHAVIORS, 2017, 69 :65-77
[2]  
[Anonymous], 2017, DRUG OVERDOSE DEATHS
[3]   Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians [J].
Bao, Yuhua ;
Pan, Yijun ;
Taylor, Aryn ;
Radakrishnan, Sharmini ;
Luo, Feijun ;
Pincus, Harold Alan ;
Schackman, Bruce R. .
HEALTH AFFAIRS, 2016, 35 (06) :1045-1051
[4]   A survey of Physicians' Perspectives on the New York State Mandatory Prescription Monitoring Program (ISTOP) [J].
Blum, Cary J. ;
Nelson, Lewis S. ;
Hoffman, Robert S. .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2016, 70 :35-43
[5]   Prescription Drug Monitoring and Dispensing of Prescription Opioids [J].
Brady, Joanne E. ;
Wunsch, Hannah ;
DiMaggio, Charles ;
Lang, Barbara H. ;
Giglio, James ;
Li, Guohua .
PUBLIC HEALTH REPORTS, 2014, 129 (02) :139-147
[6]  
Brandeis University Prescription Drug Monitoring Program Training and Technical Assistance Center, 2017, STAT PRESCR DRUG MON
[7]  
Brandeis University Prescription Drug Monitoring Program Training and Technical Assistance Center, 2018, PDMP MAND ENR PRESCR
[8]   Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity [J].
Brown, Richard ;
Riley, Moira R. ;
Ulrich, Lydia ;
Kraly, Ellen Percy ;
Jenkins, Paul ;
Krupa, Nicole L. ;
Gadomski, Anne .
DRUG AND ALCOHOL DEPENDENCE, 2017, 178 :348-354
[9]   A qualitative analysis of prescribers' and dispensers' views on improving prescription drug monitoring programs [J].
Carnes, Neal A. ;
Wright, Eric R. ;
Norwood, Connor W. .
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2017, 13 (06) :1167-1174
[10]  
Centers for Disease Control and Prevention, 2017, CHECK PDMP IMP STEP